Next |
home / stock / dmac / dmac message board
Subject | By | Source | When |
---|---|---|---|
I don't understand the lack of interest. | Cincinnatus | investorshub | 11/04/2021 10:32:05 PM |
SEC Form 4s - Multiple informative buys from insiders. | TonyJoe1957 | investorshub | 08/17/2021 11:17:19 AM |
Very dead board, but I'll try once more. | Cincinnatus | investorshub | 05/12/2021 12:08:35 AM |
Secondary - 2.1M shares @ $4 | Plegee | investorshub | 02/11/2020 9:55:20 PM |
Provisional Approval?? | Cincinnatus | investorshub | 12/20/2019 4:44:16 PM |
Anyone know where to find a list of | Cincinnatus | investorshub | 08/15/2019 4:59:26 AM |
Back under $3 | willlbone | investorshub | 07/10/2019 5:16:08 PM |
znewcar1: DMAC 29% v3,7M c4.94 f12M gap up S@4.5 H5.93 | znewcar1 | investorshangout | 06/21/2019 2:18:31 AM |
* * $DMAC Video Chart 06-20-2019 * * | ClayTrader | investorshub | 06/20/2019 9:50:15 PM |
Bad timing in IPO land. 1M traded | Cincinnatus | investorshub | 12/08/2018 5:49:03 PM |
Per S1/A DiaMedica Therapeutics Inc.'s ticker on the | Renee | investorshub | 12/07/2018 2:17:49 PM |
DMCA moved to the Nasdaq from the OTC: | Renee | investorshub | 12/07/2018 12:22:05 PM |
IPO info But incomplete because no mention | Cincinnatus | investorshub | 12/06/2018 3:29:04 PM |
DMCAF one for 20 reverse split: | Renee | investorshub | 11/14/2018 10:53:28 PM |
Can anyone effectively verify or dispute the info | Cincinnatus | investorshub | 07/20/2018 5:03:28 PM |
only down 20% since this epic call........ | OGINVU | investorshub | 07/19/2018 10:35:32 PM |
You must be pumpin this up to help | OGINVU | investorshub | 07/18/2018 1:22:08 AM |
$DMCAF is one of the most talked about | TrendTrade2016 | investorshub | 07/15/2018 12:34:09 PM |
The compound is used in Asia for an | Regis999 | investorshub | 04/16/2018 6:08:15 PM |
John Mauldins Biotech company -- DiaMedica (TSXV:DMA; OTCQB:$DMCAF) | Regis999 | investorshub | 04/16/2018 6:06:52 PM |
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ReMEDy2 Clinical Site Activation Commenced in December 2023 Strengthened Management Team with Lorianne Masuoka, M.D., as Chief Medical Officer $53 Million Cash with Runway to 2026 ...
DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developi...
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the...